EICHOR
● Completed
An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis
Condition: Psoriatic Arthritis · Sponsor: AbbVie
About this study
Psoriatic arthritis (PsA) is a chronic, immune-mediated, systemic disease affecting less than 1% of people with variations by parts of the world, and around 20%-30% of participants with psoriasis. Upadacitinib (RINVOQ) is approved drug for the treatment of adult participants with active PsA in Europe. Approximately 450 adult participants who are prescribed Upadacitinib by their physician in accordance with local label will be enrolled in 4 countries in Europe: France, Germany, Greece and Italy. Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 24 months. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (89)
| Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 252536 | Nice, Alpes-Maritimes, France | — |
| Duplicate_CH Troyes - Hopital Simone Veil /ID# 252625 | Troyes, Aube, France | — |
| Infirmerie Protestante De Lyon /ID# 252075 | Caluire-et-Cuire, Auvergne-Rhône-Alpes, France | — |
| Duplicate_CHU de Besancon - Jean Minjoz /ID# 252537 | Besançon, Doubs, France | — |
| CHU Limoges - Dupuytren 1 /ID# 252432 | Limoges, Franche-Comte, France | — |
| CHU Toulouse - Hopital Purpan /ID# 252077 | Toulouse, Haute-Garonne, France | — |
| CHU Montpellier - Hopital Saint Eloi /ID# 252078 | Montpellier, Herault, France | — |
| CHU Grenoble - Hopital Michallon /ID# 252601 | La Tronche, Isere, France | — |
| CHU Bordeaux - Hopital Pellegrin /ID# 252532 | Bordeaux, New Aquitaine, France | — |
| Ch Beauvais /Id# 252464 | Beauvais, Oise, France | — |
| Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 245194 | Créteil, Paris, France | — |
| Cabinet Medical Dr Albert-Sabonnadiere - Antibes /ID# 252523 | Antibes, Provence-Alpes-Côte d'Azur Region, France | — |
+ 77 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05616871